“Attention Shareholders: Don’t Miss Your Chance to Lead the Way – Important Deadline Reminder from Levi and Korsinsky”

Recovering Losses on AstraZeneca PLC Investment Taking Action Under Federal Securities Laws If you find yourself in a situation where you have suffered a financial loss as a result of your investment in AstraZeneca PLC (NASDAQ:AZN), it is important to understand that there may be options available to you for potential recovery. Under the federal…

Read More

Exploring the Shift: From Selling Equities to Buying Fixed Income – A Deep Dive into GGN and a Top-Rated Preferred Share Yielding 6%

Navigating the Economy: A Closer Look at the Inverted Yield Curve and Preferred Stocks In recent economic news, the yield curve has inverted, causing a ripple effect throughout the financial world. This phenomenon, where short-term interest rates are higher than long-term rates, is often seen as a warning sign of an impending recession. Amidst this…

Read More

“Unpacking Neste Oyj’s Q4 2024 Earnings Call: Insights from the Transcription”

Neste Oyj Q4 2024 Earnings Conference Call Highlights Company Participants Riikka Toivonen – Head, IR Heikki Malinen – CEO Anssi Tammilehto – Interim CFO Conference Call Participants Sasikanth Chilukuru – Morgan Stanley Pablo Cuadrado – Kepler Cheuvreux Chris Kuplent – Bank of America Artem Beletski – SEB Iiris Theman – Carnegie Peter Low – Redburn…

Read More

“Breaking News: Fusion Fuel Announces Move to Nasdaq Capital Market and Extension to Comply with Bid Price Rule”

Fusion Fuel Green PLC Moves Listing to Nasdaq Capital Market DUBLIN, Jan. 31, 2025 (GLOBE NEWSWIRE) — Fusion Fuel Green PLC (Nasdaq: HTOO), a leading provider of energy engineering solutions, announced that it was approved to transfer its Class A Ordinary Shares and warrants to The Nasdaq Capital Market from The Nasdaq Global Market. The…

Read More

Cargo Therapeutics Announces Discontinuation of FIRCE 1 Phase 2 Study for Firi-cel, Shifts Focus to Remaining Programs and Explores Strategic Options

CARGO Announces Discontinuation of FIRCE-1 Study and Workforce Reduction In a recent press release, CARGO Therapeutics, a clinical-stage biotechnology company focused on developing cellular therapies for the treatment of cancer, announced the discontinuation of its Phase 2 clinical study, FIRCE-1, for firicabtagene autoleucel (firi-cel). This decision was made based on the belief that the study…

Read More